AstraZeneca’s FluMist is a needle-free nasal spray with comparable effectiveness and acceptable safety relative to other flu vaccines, according to an Oct. 24 company news release. If approved, it would be eligible for patients 2 to 49 years old.
The FDA is expected to make a regulatory decision in the first quarter of 2024, and if approved, FluMist would be available for the 2024-25 flu season.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
